MedTrace Logo

Clinical Study Evaluating the Effect of Carvedilol in Patients With Active Rheumatoid Arthritis

NCT06108518 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-04-16

No results posted yet for this study

Summary

This study aims at investigating the possible efficacy and safety of carvedilol as an adjunctive therapy in patients with active rheumatoid arthritis and hypertension.

Conditions

Interventions

DRUG

Carvedilol

Treatment group will take carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Dr/Tarek Mohamed, Professor · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-10-31
Completion
2024-11-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06108518 on ClinicalTrials.gov